Model-Based Analysis of Impact, Costs, and Cost-effectiveness of Tuberculosis Outbreak Investigations, United States

被引:0
|
作者
Shrestha, Sourya [1 ]
Cilloni, Lucia [1 ]
Asay, Garrett R. Beeler [2 ]
Kammerer, J. Steve [2 ]
Raz, Kala [2 ]
Shaw, Tambi [3 ]
Cilnis, Martin [3 ]
Wortham, Jonathan [2 ]
Marks, Suzanne M. [2 ]
Dowdy, David [1 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] CDCP, Atlanta, GA USA
[3] Calif Dept Publ Hlth, Richmond, CA USA
关键词
MYCOBACTERIUM-TUBERCULOSIS; LATENT; INFECTION; TRANSMISSION; INDIVIDUALS; RIFAPENTINE; REGIMEN; DISEASE;
D O I
10.3201/eid3103.240633
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Outbreak investigation is an essential component of tuberculosis (TB) control in the United States, but its epidemiologic impact and cost-effectiveness have not been quantified. We modeled outbreak investigation activities in the United States during 2023-2032 and estimated corresponding epidemiologic impact, economic costs (in 2022 US$), and incremental cost-effectiveness ratios from the healthcare system perspective (cost per additional quality-adjusted life-year gained). We projected that outbreak investigations would result in 1,030,000 (95% uncertainty interval [UI] 376,000- 1,740,000) contacts investigated, leading to 4,130 (95% UI 1,420-7,640) TB diagnoses and 104,000 (95% UI 37,600-181,000) latent TB infection diagnoses, at a total cost of US $219 million (95% UI $80-$387 million). We estimated that 5,560 (95% UI 1,720-11,400) TB cases would be averted through early detection and treatment, and the incremental cost-effectiveness of outbreak investigations, compared with no outbreak investigations, was $27,800 per quality-adjusted life-year gained (95% UI $4,580-$68,700).
引用
收藏
页码:497 / 506
页数:10
相关论文
共 50 条
  • [31] Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis
    Norum, J.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 532 - 537
  • [32] Expanded screening for HIV in the United States - An analysis of cost-effectiveness
    Paltiel, AD
    Weinstein, MC
    Kimmel, AD
    Seage, GR
    Losina, E
    Zhang, H
    Freedberg, KA
    Walensky, RP
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06): : 586 - 595
  • [33] Cost-Effectiveness Analysis of Lung Cancer Screening in the United States
    Young, Robert P.
    Hopkins, Raewyn J.
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (10) : 705 - 706
  • [34] Cost-effectiveness analysis of a rotavirus immunization program for the United States
    Tucker, AW
    Haddix, AC
    Bresee, JS
    Holman, RC
    Parashar, UD
    Glass, RI
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (17): : 1371 - 1376
  • [35] THE ESTIMATED IMPACT AND COST-EFFECTIVENESS OF NONAVALENT HPV VACCINATION IN THE UNITED STATES
    Chesson, H. W.
    Markowitz, L. E.
    Hariri, S.
    Ekwueme, D. U.
    Saraiya, M.
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A61 - A62
  • [36] Costs and thresholds in cost-effectiveness analysis
    Sartore, M. E.
    Kamal, K. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (10) : 1455 - 1456
  • [37] The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis
    Andrews, Jason R.
    Lawn, Stephen D.
    Rusu, Corina
    Wood, Robin
    Noubary, Farzad
    Bender, Melissa A.
    Horsburgh, C. Robert
    Losina, Elena
    Freedberg, Kenneth A.
    Walensky, Rochelle P.
    AIDS, 2012, 26 (08) : 987 - 995
  • [38] Survivor costs in cost-effectiveness analysis
    Gandjour, A
    ANNALS OF INTERNAL MEDICINE, 2006, 144 (07) : 534 - 535
  • [39] Indirect costs and cost-effectiveness analysis
    Ernst, Richard
    VALUE IN HEALTH, 2006, 9 (04) : 253 - 261
  • [40] Estimating ‘Costs’ for Cost-Effectiveness Analysis
    Alec Miners
    PharmacoEconomics, 2008, 26 : 745 - 751